CN107108624B - 用于治疗耐药性细菌感染的组合疗法 - Google Patents

用于治疗耐药性细菌感染的组合疗法 Download PDF

Info

Publication number
CN107108624B
CN107108624B CN201580062519.5A CN201580062519A CN107108624B CN 107108624 B CN107108624 B CN 107108624B CN 201580062519 A CN201580062519 A CN 201580062519A CN 107108624 B CN107108624 B CN 107108624B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
sulbactam
compound
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580062519.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107108624A (zh
Inventor
鲍德韦因·洛德韦克玛利亚·德扬
托马斯·佛朗索瓦·杜兰德-雷维尔
杰伦·库涅拉·维尔海连
鲁本·托马斯
约翰·穆勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ntassis Treatment
Original Assignee
Ntasis Therapeutic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ntasis Therapeutic Co Ltd filed Critical Ntasis Therapeutic Co Ltd
Publication of CN107108624A publication Critical patent/CN107108624A/zh
Application granted granted Critical
Publication of CN107108624B publication Critical patent/CN107108624B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580062519.5A 2014-11-17 2015-11-17 用于治疗耐药性细菌感染的组合疗法 Active CN107108624B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17
US62/080,667 2014-11-17
PCT/US2015/061076 WO2016081452A1 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Publications (2)

Publication Number Publication Date
CN107108624A CN107108624A (zh) 2017-08-29
CN107108624B true CN107108624B (zh) 2020-01-07

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580062519.5A Active CN107108624B (zh) 2014-11-17 2015-11-17 用于治疗耐药性细菌感染的组合疗法

Country Status (31)

Country Link
US (2) US9968593B2 (https=)
EP (1) EP3221313B1 (https=)
JP (1) JP6764862B2 (https=)
KR (1) KR102542392B1 (https=)
CN (1) CN107108624B (https=)
AU (1) AU2015350128B2 (https=)
BR (1) BR112017010132B1 (https=)
CA (1) CA2966632C (https=)
CY (1) CY1121384T1 (https=)
DK (1) DK3221313T3 (https=)
EA (1) EA033829B1 (https=)
ES (1) ES2717776T3 (https=)
HK (1) HK1244798B (https=)
HR (1) HRP20190580T1 (https=)
HU (1) HUE044061T2 (https=)
IL (1) IL251979B (https=)
LT (1) LT3221313T (https=)
ME (1) ME03357B (https=)
MX (1) MX2017006383A (https=)
MY (1) MY196240A (https=)
PH (1) PH12017500852B1 (https=)
PL (1) PL3221313T3 (https=)
PT (1) PT3221313T (https=)
RS (1) RS58429B1 (https=)
SG (1) SG11201703633TA (https=)
SI (1) SI3221313T1 (https=)
SM (1) SMT201900187T1 (https=)
TR (1) TR201905233T4 (https=)
TW (1) TWI690317B (https=)
WO (1) WO2016081452A1 (https=)
ZA (1) ZA201703245B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6764862B2 (ja) 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
DK3512851T3 (en) * 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
WO2018208769A1 (en) 2017-05-08 2018-11-15 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
ES2953362T3 (es) * 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
CN110269857A (zh) * 2018-03-14 2019-09-24 正大天晴药业集团股份有限公司 含阿维巴坦的抗菌组合物及其用途
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
ES3004932T3 (en) * 2020-04-02 2025-03-13 Glaxosmithkline Ip Dev Ltd Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
CA3205756A1 (en) * 2021-01-20 2022-07-28 Entasis Therapeutics Limited Fixed dosage antibiotic compositions
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
WO2025239896A1 (en) * 2024-05-16 2025-11-20 Entasis Therapeutics, Inc. Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
CN103648496A (zh) * 2011-07-26 2014-03-19 沃克哈特有限公司 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物
WO2014122468A1 (en) * 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
CN104364254A (zh) * 2012-04-02 2015-02-18 阿斯利康(瑞典)有限公司 作为β-内酰胺酶抑制剂的杂二环化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282567B6 (cs) 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
WO2009091856A2 (en) * 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
NZ616806A (en) 2011-07-26 2015-03-27 Wockhardt Ltd Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX348974B (es) 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CA2845108C (en) 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
CA2846107C (en) 2011-09-13 2016-06-21 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
WO2013149136A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
RU2614418C2 (ru) 2012-08-25 2017-03-28 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
JP6764862B2 (ja) 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648496A (zh) * 2011-07-26 2014-03-19 沃克哈特有限公司 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物
CN104364254A (zh) * 2012-04-02 2015-02-18 阿斯利康(瑞典)有限公司 作为β-内酰胺酶抑制剂的杂二环化合物
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
WO2014122468A1 (en) * 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia

Also Published As

Publication number Publication date
AU2015350128B2 (en) 2019-05-16
CA2966632A1 (en) 2016-05-26
JP2017533945A (ja) 2017-11-16
ZA201703245B (en) 2019-08-28
IL251979B (en) 2020-10-29
BR112017010132A2 (pt) 2018-01-02
EP3221313B1 (en) 2019-01-09
PL3221313T3 (pl) 2019-07-31
RS58429B1 (sr) 2019-04-30
PT3221313T (pt) 2019-04-15
EP3221313A1 (en) 2017-09-27
TR201905233T4 (tr) 2019-05-21
JP6764862B2 (ja) 2020-10-07
MY196240A (en) 2023-03-24
US20180000800A1 (en) 2018-01-04
BR112017010132B1 (pt) 2023-02-14
EA201791069A1 (ru) 2017-11-30
SG11201703633TA (en) 2017-06-29
IL251979A0 (en) 2017-06-29
HRP20190580T1 (hr) 2019-05-17
KR20170082635A (ko) 2017-07-14
TW201625234A (zh) 2016-07-16
HUE044061T2 (hu) 2019-09-30
ME03357B (me) 2019-10-20
AU2015350128A1 (en) 2017-06-01
ES2717776T3 (es) 2019-06-25
US20180289681A1 (en) 2018-10-11
US9968593B2 (en) 2018-05-15
MX2017006383A (es) 2017-08-21
EA033829B1 (ru) 2019-11-29
NZ731601A (en) 2024-02-23
HK1244798B (en) 2020-02-21
CN107108624A (zh) 2017-08-29
CA2966632C (en) 2023-10-03
SI3221313T1 (sl) 2019-04-30
PH12017500852B1 (en) 2023-03-08
KR102542392B1 (ko) 2023-06-09
US10376499B2 (en) 2019-08-13
LT3221313T (lt) 2019-03-25
DK3221313T3 (en) 2019-04-08
PH12017500852A1 (en) 2017-11-06
CY1121384T1 (el) 2020-05-29
WO2016081452A1 (en) 2016-05-26
SMT201900187T1 (it) 2019-05-10
TWI690317B (zh) 2020-04-11

Similar Documents

Publication Publication Date Title
CN107108624B (zh) 用于治疗耐药性细菌感染的组合疗法
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
TW201632177A (zh) 有效對抗包括抗藥性微生物類之微生物群的組合治療
US9814754B2 (en) Combinations with a backbone-cyclized peptide
CN105792827B (zh) 抗菌组合物
CN106794250A (zh) 包含抗菌剂的药物组合物
CN106029068A (zh) 包含抗菌剂的药物组合
CN106659718A (zh) 包含抗菌剂的药物组合物
CN106102741A (zh) 包含抗菌剂的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: British diesel

Applicant after: ASTRAZENECA AB

Address before: London, England

Applicant before: ASTRAZENECA AB

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250827

Address after: Delaware, USA

Patentee after: Ntassis treatment

Country or region after: U.S.A.

Address before: British diesel

Patentee before: ASTRAZENECA AB

Country or region before: United Kingdom